Notice of Award of a Single-Source Cooperative Agreement To Fund the National Institute for Communicable Diseases, Republic of South Africa, 39432 [2023-12963]
Download as PDF
<![CDATA[
39432
Federal Register / Vol. 88, No. 116 / Friday, June 16, 2023 / Notices
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than July 17, 2023.
A. Federal Reserve Bank of Richmond
(Brent B. Hassell, Assistant Vice
President) P.O. Box 27622, Richmond,
Virginia 23261. Comments can also be
sent electronically to
Comments.applications@rich.frb.org:
1. Affinity Bancshares, Inc.,
Covington, Georgia; to become a bank
holding company upon the charter
conversion of its subsidiary, Affinity
Bank, also of Covington, Georgia, from
a federal stock savings bank to a
national bank.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
ddrumheller on DSK120RN23PROD with NOTICES1
[FR Doc. 2023–12955 Filed 6–15–23; 8:45 am]
BILLING CODE 6210–01–P
VerDate Sep<11>2014
17:43 Jun 15, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Award of a Single-Source
Cooperative Agreement To Fund the
National Institute for Communicable
Diseases, Republic of South Africa
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice.
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
award of approximately $2,000,000,
with an expected total funding of
approximately $11,500,000 over a fiveYear period, to the National Institute for
Communicable Diseases, Republic of
South Africa. The award will support
research studies on influenza and other
respiratory pathogens of public health
import in South Africa.
SUMMARY:
The period for this award will be
September 1, 2024 through August 31,
2029.
DATES:
Dr.
Amy Yang, National Center for HIV,
Viral Hepatitis, STD, and TB
Prevention, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop US8–1, Atlanta, Georgia 30329
Telephone: 404–718–8836. Email:
AYang@cdc.gov.
FOR FURTHER INFORMATION CONTACT:
The
single-source award will conduct
research on surveillance (including
epidemiology, disease burden,
transmission, and laboratory methods),
preventive tools and strategies (e.g.,
vaccines, antivirals), and strategies for
increasing coverage of morbidity and
mortality mitigating interventions. Data
will be used to inform prioritization of
public health interventions in high-risk
populations in South Africa, regionally
and globally.
The National Institute for
Communicable Diseases is in a unique
position to conduct this work, as it is
the only sufficiently advanced
governmental research, public health
institute, and laboratory in the subregion that can perform sophisticated
studies and laboratory analyses required
to understand influenza disease burden,
evaluate intervention efficacy and
effectiveness, and intervention scale-up
that is in the Southern Hemisphere.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Summary of the Award
Recipient: National Institute for
Communicable Diseases, Republic of
South Africa
Purpose of the Award: The purpose of
this award is to conduct research
studies on influenza and other
respiratory pathogens of public health
import in South Africa, specifically,
focusing on surveillance (including
epidemiology, disease burden,
transmission, and laboratory methods),
preventive tools and strategies (e.g.,
vaccines, antivirals), and strategies for
increasing coverage of morbidity and
mortality mitigating interventions. Data
will be used to inform prioritization of
public health interventions in high-risk
populations in South Africa, regionally
and globally.
Amount of Award: $2,000,000 in
Federal fiscal year (FFY) 2024 funds,
with a total estimated $11,500,000 for
the 5-year period of performance,
subject to availability of funds.
Authority: This program is authorized
under Public Health Service Act, section
307 [42 U.S.C. 242l], as amended.
Period of Performance: September 1,
2024 through August 31, 2029.
Dated: June 13, 2023.
Terrance Perry,
Chief Grants Management Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2023–12963 Filed 6–15–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–23–1308]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Validated
Interview and Survey of Outpatient
Providers on Antibiotic Stewardship
Interventions to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on March 31,
2023, to obtain comments from the
public and affected agencies. CDC
received two comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
E:\FR\FM\16JNN1.SGM
16JNN1
]]>Agencies
[Federal Register Volume 88, Number 116 (Friday, June 16, 2023)]
[Notices]
[Page 39432]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-12963]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Single-Source Cooperative Agreement To Fund
the National Institute for Communicable Diseases, Republic of South
Africa
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $2,000,000, with an expected total funding of
approximately $11,500,000 over a five-Year period, to the National
Institute for Communicable Diseases, Republic of South Africa. The
award will support research studies on influenza and other respiratory
pathogens of public health import in South Africa.
DATES: The period for this award will be September 1, 2024 through
August 31, 2029.
FOR FURTHER INFORMATION CONTACT: Dr. Amy Yang, National Center for HIV,
Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control
and Prevention, 1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia
30329 Telephone: 404-718-8836. Email: [email protected].
SUPPLEMENTARY INFORMATION: The single-source award will conduct
research on surveillance (including epidemiology, disease burden,
transmission, and laboratory methods), preventive tools and strategies
(e.g., vaccines, antivirals), and strategies for increasing coverage of
morbidity and mortality mitigating interventions. Data will be used to
inform prioritization of public health interventions in high-risk
populations in South Africa, regionally and globally.
The National Institute for Communicable Diseases is in a unique
position to conduct this work, as it is the only sufficiently advanced
governmental research, public health institute, and laboratory in the
sub-region that can perform sophisticated studies and laboratory
analyses required to understand influenza disease burden, evaluate
intervention efficacy and effectiveness, and intervention scale-up that
is in the Southern Hemisphere.
Summary of the Award
Recipient: National Institute for Communicable Diseases, Republic
of South Africa
Purpose of the Award: The purpose of this award is to conduct
research studies on influenza and other respiratory pathogens of public
health import in South Africa, specifically, focusing on surveillance
(including epidemiology, disease burden, transmission, and laboratory
methods), preventive tools and strategies (e.g., vaccines, antivirals),
and strategies for increasing coverage of morbidity and mortality
mitigating interventions. Data will be used to inform prioritization of
public health interventions in high-risk populations in South Africa,
regionally and globally.
Amount of Award: $2,000,000 in Federal fiscal year (FFY) 2024
funds, with a total estimated $11,500,000 for the 5-year period of
performance, subject to availability of funds.
Authority: This program is authorized under Public Health Service
Act, section 307 [42 U.S.C. 242l], as amended.
Period of Performance: September 1, 2024 through August 31, 2029.
Dated: June 13, 2023.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023-12963 Filed 6-15-23; 8:45 am]
BILLING CODE 4163-18-P
